Yahoo Finance17d
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Complete response at week 8: At week 8, 21 patients (53.8%) achieved a complete response (95% confidence interval (CI): 37.2–69.9%). Complete response at any time: 33 patients (85%) achieved a ...
Mena FN17d
New Data For Emapalumab In The Treatment Of Macrophage Activation Syndrome To Be Presented At The ACR Conference
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's ...
PR Newswire17d
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory ...
Stockhouse17d
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Grom, MD, Professor of Paediatrics, Research Director Division of Rheumatology, Cincinnati Children's Hospital Medical Centre, in a session entitled "Efficacy and Safety of emapalumab in children and ...